Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2434764rdf:typepubmed:Citationlld:pubmed
pubmed-article:2434764lifeskim:mentionsumls-concept:C0008972lld:lifeskim
pubmed-article:2434764lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:2434764lifeskim:mentionsumls-concept:C0682756lld:lifeskim
pubmed-article:2434764pubmed:dateCreated1987-4-17lld:pubmed
pubmed-article:2434764pubmed:abstractTextThe effect of circulating arginine vasopressin (AVP) on blood pressure, heart rate, and skin blood flow was assessed in normotensive subjects, mild hypertensive patients, and patients with congestive heart failure, utilizing the specific antagonist of AVP at the vascular receptor level, d(CH2)5Tyr(Me)AVP (5 micrograms/kg i.v.). The renin system of the normal volunteers treated with the AVP antagonist was either intact or acutely blocked with the angiotensin converting-enzyme inhibitor captopril (25 mg p.o.). In some volunteers, the cardiovascular effect of AVP released by Finnish sauna or cigarette smoking was studied. In patients with congestive heart failure, hemodynamic measurements (pressures and cardiac output) were obtained invasively. Acute blockade of AVP vascular receptors produced no cardiovascular effect unless plasma AVP levels were markedly elevated. In our experience, abnormally high circulating AVP appears to be responsible for the decrease in skin blood flow induced by cigarette smoking and to some extent for the maintenance of vascular tone in the rare patients with particularly severe congestive heart failure.lld:pubmed
pubmed-article:2434764pubmed:languageenglld:pubmed
pubmed-article:2434764pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2434764pubmed:citationSubsetIMlld:pubmed
pubmed-article:2434764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2434764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2434764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2434764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2434764pubmed:statusMEDLINElld:pubmed
pubmed-article:2434764pubmed:issn0160-2446lld:pubmed
pubmed-article:2434764pubmed:authorpubmed-author:NussbergerJJlld:pubmed
pubmed-article:2434764pubmed:authorpubmed-author:BrunnerH RHRlld:pubmed
pubmed-article:2434764pubmed:authorpubmed-author:WaeberBBlld:pubmed
pubmed-article:2434764pubmed:authorpubmed-author:NicodPPlld:pubmed
pubmed-article:2434764pubmed:authorpubmed-author:HofbauerK GKGlld:pubmed
pubmed-article:2434764pubmed:issnTypePrintlld:pubmed
pubmed-article:2434764pubmed:volume8 Suppl 7lld:pubmed
pubmed-article:2434764pubmed:ownerNLMlld:pubmed
pubmed-article:2434764pubmed:authorsCompleteYlld:pubmed
pubmed-article:2434764pubmed:paginationS111-6lld:pubmed
pubmed-article:2434764pubmed:dateRevised2008-8-16lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:meshHeadingpubmed-meshheading:2434764-...lld:pubmed
pubmed-article:2434764pubmed:year1986lld:pubmed
pubmed-article:2434764pubmed:articleTitleClinical studies with a vascular vasopressin antagonist.lld:pubmed
pubmed-article:2434764pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2434764pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed